List view / Grid view
Newly appointed Vice President of Medical Affairs, Europe at BeiGene, Dr Jan-Henrik Terwey, provides exclusive insight on clinical development in the haematology/oncology space, and highlights significant data for its BCL-2 inhibitor, sonrotoclax.
Approval of BeiGene’s TEVIMBRA® (tislelizumab) in EU follows an agreement with Novartis to regain global rights of the antibody treatment.
When France's ATU reform was implemented, some viewed it as restrictive. Here, Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases.
Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.
According to a new study, Drug Ranking Using Machine Learning (DRUML) can accurately rank cancer therapies by efficacy across a range of cancer types.
Researchers at NYU Langone Health's Perlmutter Cancer Center report that at least three kinds of bacteria in the mouths of Americans may directly affect their risk of developing oesophageal cancer.
Proton beam therapy, in combination with chemotherapy, may be a better treatment option than traditional radiation therapy techniques...
Brazilian researchers have investigated whether cisplatin and 5-FU would interfere with the protein pRB...
